Chang E

No ORCID on file · 4 papers in corpus · active 2022-2024

Study types

  • meta-analysis 1
  • other 1

Condition tags

  • endometriosis 2
  • dysmenorrhea 1
  • chronic_pelvic_pain 1
  • dyspareunia 1
other 2024
Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
Expert opinion on drug safety ·doi:10.1080/14740338.2024.2351451

OBJECTIVE: Elagolix is approved for the treatment of moderate-to-severe pain associated with endometriosis. However, the long-term safety of elagolix in a large sample of real-world patients is unknown. METHODS: The U.S. Food and Drug Admi…

meta-analysis 2024
The short- and mid-term efficacy and safety of elagolix in the management of pain associated with endometriosis: A systematic review and meta-analysis
Journal of gynecology obstetrics and human reproduction ·doi:10.1016/j.jogoh.2024.102829

BACKGROUND: Elagolix, an approved non-peptide GnRH antagonist, shows promise in relieving endometriosis-related pain, but its short- and mid-term efficacy and potential side effects are still under investigation. OBJECTIVE: The aim is to p…

2023
Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management.
Cell reports. Medicine ·doi:10.1016/j.xcrm.2023.101292

Glucagon-like peptide-1 (GLP-1) is an incretin hormone and neurotransmitter secreted from intestinal L cells in response to nutrients to stimulate insulin and block glucagon secretion in a glucose-dependent manner. Long-acting GLP-1 recepto…

2022
Predictive value of Leukocyte ImmunoTest (LIT™) in cancer patients: a prospective cohort study.
Frontiers in oncology ·doi:10.3389/fonc.2022.897968

Early diagnosis of cancer is crucial to initiate prompt treatment for better patient outcomes. The host immune function and its associated modulators are considered to be potential biomarkers for early cancer diagnosis. Immune and immune-ch…